HPV Vaccine for Adults: Who Benefits Up to 45 and What the Evidence Shows

A woman in her late thirties recently told me she had spent twenty minutes in a pharmacy line reading the small print on a vaccine poster, trying to work out whether the phrase ‘through age 45’ applied to her. She had grown up hearing the HPV vaccine was for teenagers. Now the number on the wall said otherwise, and nobody seemed able to explain the gap.

She is not alone. As of June 2025, searches for the hpv vaccine for adults have climbed sharply, pushed by two things at once: US regulators approving self-collected HPV samples for cervical screening, first in clinics in 2024 and then as an at-home kit in May 2025, and a wave of social posts insisting that anyone past 26 has simply missed the boat. One of those developments is genuinely important. The other is wrong, but not for the reason most people assume.

What follows is the honest version: who benefits, how much, how we know, and where the evidence thins out.

Why the HPV vaccine for adults is suddenly everywhere

Two very different stories collided this year. The first is about screening. Human papillomavirus, or HPV, is a family of more than 200 related viruses, a dozen or so of which can cause cancer, and for decades the only way to check a cervix for those high-risk types was a speculum examination in a clinic. In 2024 US regulators cleared self-collected vaginal swabs for HPV testing in health-care settings, and in May 2025 an at-home self-collection option followed. Self-collection is now part of mainstream screening conversations, and that has put the letters H-P-V back in front of millions of adults who had filed the topic under ‘school’.

The second story is older but keeps resurfacing. In October 2018 the US Food and Drug Administration expanded approval of the 9-valent HPV vaccine to include people aged 27 to 45. The following June, the CDC’s Advisory Committee on Immunization Practices decided not to recommend routine vaccination for that age group but instead to endorse what it calls shared clinical decision-making: a conversation between patient and clinician about individual benefit. That nuance travels badly on social media. It has been compressed into ‘the vaccine works until 45’ by some and ‘it is pointless after 26’ by others.

Neither summary is accurate, and the confusion is costing people the chance to make a reasoned choice. The truth sits in the middle and depends on a handful of facts about how HPV spreads, how the vaccine works, and what the trials in adults actually measured. It also depends on something that rarely makes it into a headline: the vaccine only prevents infections you have not yet acquired, which is why age matters so much more for HPV than for, say, a tetanus booster.

What changed recently: the dated facts

A short timeline clears up most of the noise. In 2006 the first HPV vaccine was licensed in the United States for females aged 9 to 26, targeting four HPV types. Males were added in 2009. In December 2014 the 9-valent vaccine was approved, covering nine types and, according to the National Cancer Institute, roughly 90 percent of cervical cancers rather than the 70 percent covered by the earlier products.

October 2018 is the date that matters for adults: the FDA extended the 9-valent vaccine’s approval to ages 27 through 45, based on a randomized trial of the earlier four-type vaccine in women of that age plus studies showing that the newer vaccine produced comparable antibody levels. In June 2019 the CDC’s advisory committee reviewed the same data and settled on shared clinical decision-making for 27 to 45, keeping routine recommendations at ages 11 to 12 and catch-up through 26. That remains the current CDC position.

Internationally, the direction of travel has been toward simpler schedules rather than older ages. In 2022 the World Health Organization endorsed a shortened dosing approach for girls and young women, and in September 2023 the NHS in England moved its routine adolescent program to a simplified schedule too. The NHS continues to offer catch-up vaccination to people up to their 25th birthday who missed it at school, and to men who have sex with men up to age 45 through sexual health clinics.

Then came screening. The 2024 clinic-based self-collection approval and the May 2025 at-home kit approval changed how adults encounter HPV testing, though not who should be screened or when. Put together, the changes explain the surge in questions. Regulators have widened the age window for the vaccine, public health bodies have been more cautious about who gains most, and new screening tools have made HPV a household word again. None of these steps altered the underlying biology, which is where we turn next.

Should adults get vaccinated for HPV? What CDC, WHO and NHS actually say

The three big guidance bodies agree on the core and differ at the edges. The CDC recommends routine HPV vaccination at ages 11 to 12, notes that the series can start at age 9, and recommends catch-up vaccination for everyone through age 26 who was not adequately vaccinated earlier. For adults aged 27 through 45, the CDC does not recommend vaccination for everyone but says some people in that range who are not already vaccinated may benefit after discussing it with a clinician. Above 45, the CDC does not recommend vaccination, and the vaccine is not licensed for that age in the US.

The WHO’s fact sheet on HPV and cancer frames the issue from a global elimination standpoint. Its primary target group is girls aged 9 to 14, before most have any sexual exposure, because that is where each dose prevents the most cancer. Secondary target groups, including older adolescents and young women, are recommended where feasible and affordable. The WHO does not set a specific adult upper age but stresses that vaccinating before exposure is what drives population-level results.

The NHS offers the vaccine at ages 12 to 13 in school and allows anyone eligible who missed it to catch up until their 25th birthday. Men who have sex with men, along with some transgender people, can receive it up to age 45 at sexual health clinics, reflecting a higher risk of anal and throat cancers in that group.

So should adults get vaccinated? If you are 26 or younger and unvaccinated, every one of these bodies says yes, and the case is strong. If you are 27 to 45 in the US, the honest answer is ‘possibly, depending on your circumstances’, and the person who can weigh those circumstances with you is your prescribing clinician. The vaccine is a preventive tool, not a test or a treatment, so the question is really about how much unexposed future you still have ahead of you.

When is it too late to get vaccinated for HPV?

There is no birthday on which the vaccine stops working. What declines is the amount of protection it has left to offer, and that decline is driven by exposure, not by age itself. Most sexually active people acquire at least one HPV type within a few years of becoming active; the CDC estimates that almost everyone who is sexually active will get HPV at some point in life. The immune system clears the great majority of these infections within a year or two, but once a particular type has established a persistent infection in cervical, anal or throat tissue, the vaccine cannot remove it.

The vaccine works by teaching the immune system to recognise the outer shell of specific HPV types before they arrive. It is like installing a lock on a door: extremely effective against anyone who has not yet come through, irrelevant to anyone already inside. That is why the Swedish population study published in 2020, which followed more than 1.6 million girls and women, found that those vaccinated before age 17 had an 88 percent lower rate of invasive cervical cancer, while those vaccinated between 17 and 30 saw a 53 percent reduction. Same vaccine, different amount of door left to lock.

Where does that leave a 30- or 40-year-old? Not without hope. The 9-valent vaccine covers nine HPV types, and even someone who has encountered two or three of them is very unlikely to have met all nine. Adults who are starting new relationships after divorce or bereavement, who have had few previous partners, or who have a new risk factor such as an immune-suppressing condition may still gain meaningful protection. Adults in a long monogamous relationship with no expectation of new partners will gain very little.

‘Too late’, then, is not a number. It is a judgment about future exposure that only you and a clinician who knows your history can make. The regulatory ceiling of 45 exists because that is the oldest age that has been studied, not because something changes overnight at 46.

Can you get the HPV vaccine over 45?

In the United States, no, not under the current license. The 9-valent HPV vaccine is approved through age 45, and the CDC does not recommend it above that age. This is one of the places where the honest answer is simply that the data stop. The randomized trial that supported adult approval enrolled women aged 24 to 45; no comparable trial has enrolled people in their fifties or sixties, and the vaccine’s safety and effectiveness in that group have not been formally evaluated.

Several things make older-age trials unattractive to run. Efficacy trials measure how many new infections or precancers the vaccine prevents compared with placebo. In a population where most people have already encountered the common HPV types and where the rate of new infection is low, you would need to follow a very large number of people for a very long time to detect any difference. Immune responses also tend to weaken with age, so it is not safe to assume antibody levels would match those seen in younger adults without measuring them.

Could a clinician offer it anyway? Prescribing a licensed vaccine outside its approved age would be off-label, which means outside the population studied and approved by regulators. This article does not encourage that. If you are over 45 and worried about HPV, the evidence-based path is screening: cervical screening continues to age 65 in the US under most guidelines, and the NHS screens until 64. Screening detects the persistent infections and cell changes that vaccination cannot reverse, and it is the intervention with the strongest evidence in this age group.

One caveat for completeness. Guidance evolves, and other countries have different licensing decisions. Anyone over 45 with a specific reason for concern, such as a new diagnosis affecting immunity, should raise it with their clinician rather than rely on general rules. The decision, as always with a prescription vaccine, belongs to the treating clinician.

Is it worth getting the HPV vaccine at 40? Thinking through the 27–45 window

Picture two 40-year-olds. The first has been in a mutually monogamous relationship for fifteen years, has had normal cervical screening throughout, and expects nothing to change. The second is newly single after a long marriage, is starting to date, and has just learned that a close relative had cervical cancer. Same age, entirely different calculation.

The CDC built shared clinical decision-making around exactly this variability. The committee’s own modelling in 2019 found that extending vaccination to all adults up to 45 would prevent relatively few additional cancers per person vaccinated compared with adolescent vaccination, because so much exposure has already occurred by that age. Yet the same analysis acknowledged that individual adults with limited past exposure and likely future exposure could benefit substantially. A blanket ‘yes’ would waste effort; a blanket ‘no’ would deny protection to people who could use it.

Questions that help a clinician weigh the decision include how many sexual partners a person has had, whether new partners are likely, whether a person has a condition or treatment that weakens immunity, and whether they have already had an HPV-related diagnosis. None of these are tests of virtue, and a good clinician will ask them matter-of-factly. What does not help is a blood test for HPV antibodies or a cervical HPV test to decide eligibility; neither reliably shows which of the nine vaccine types you have and have not encountered, so guidance does not recommend testing before vaccination.

Men and women face the same logic. HPV vaccination in men prevents genital warts and is expected to reduce anal, penile and throat cancers, which in the US now outnumber cervical cancers caused by HPV. Men who have sex with men are specifically called out in NHS guidance up to 45 because their risk of anal cancer is higher.

Is it worth it at 40? For the second person in our example, quite possibly. For the first, probably not. The person who decides is the clinician sitting across from you, informed by the facts of your life rather than the number on your driving licence.

What the evidence actually says, graded by strength

Evidence comes in tiers, and the HPV vaccine story spans all of them. Randomized controlled trials, where participants are assigned by chance to vaccine or placebo, sit at the top. Observational studies, which follow real populations without random assignment, come next. Expert opinion and modelling sit below. Here is how the adult question stacks up.

For adolescents and young adults through 26, the evidence is as strong as vaccine science gets. Large randomized trials in tens of thousands of participants showed near-complete protection against persistent infection and precancerous cervical changes caused by the targeted HPV types in people who had not been previously exposed. Follow-up now exceeds a decade with no sign of waning protection. Population data have confirmed the trial results: the Swedish registry study found an 88 percent reduction in invasive cervical cancer among those vaccinated before 17, and English data have shown similar large declines in cervical cancer and precancer in the first vaccinated cohorts. Grade: high.

For women aged 27 to 45, the evidence is moderate. One randomized trial of the earlier four-type vaccine in women aged 24 to 45 found roughly 88 percent efficacy against combined infection and disease from the covered types among women who completed the series and were uninfected with those types at baseline. In the wider intention-to-treat group, which included women with existing infections, efficacy was far lower, which is exactly what the biology predicts. The 9-valent vaccine was not tested in a separate efficacy trial in this age group; its approval rested on immunobridging, meaning it produced antibody levels in 27- to 45-year-olds comparable to those seen in younger people where efficacy is proven. Grade: moderate, resting on one efficacy trial plus immune-response data.

For men over 26, there is no dedicated efficacy trial; the recommendation is extrapolated from trials in younger men and from immune-response data. Grade: low to moderate.

For anyone over 45, there is no efficacy or safety trial. Grade: no direct evidence. Recognising these gradients is not scepticism about the vaccine; it is the reason guidance is confident about teenagers and deliberately conversational about adults.

HPV vaccine for adults at a glance

Guidance is easier to hold in the head when it is laid side by side. The table below summarises current recommendations and the strength of the evidence behind each age band, drawing on CDC, WHO and NHS positions. It is a starting point for a conversation, not a substitute for one.

Age group	CDC (US)	NHS (England)	Evidence for benefit
9 to 12	Routine vaccination recommended, ideally at 11 to 12	Offered at school, ages 12 to 13	High: randomized trials plus population cancer data
13 to 26	Catch-up vaccination recommended for anyone not adequately vaccinated	Catch-up available until 25th birthday for those who missed it	High: randomized trials, with benefit declining as exposure accumulates
27 to 45	Shared clinical decision-making; not routinely recommended for all	Not routinely offered; men who have sex with men eligible to 45 via sexual health clinics	Moderate: one randomized trial in women plus immune-response data
Over 45	Not recommended; vaccine not licensed for this age	Not offered	None: no efficacy or safety trials

Three things stand out. First, the two systems converge almost exactly for people under 26. Second, the 27 to 45 band is where individual circumstances rather than age drive the answer, and where the NHS has chosen a targeted approach based on cancer risk rather than a universal one. Third, the WHO, working across countries with wildly different resources, puts its weight on the youngest group because that is where each vaccination prevents the most cancer.

The ‘evidence for benefit’ column deserves a second look. Moderate evidence does not mean the vaccine is unlikely to work in a 35-year-old; it means the protection has been shown in a smaller body of research, in women only, and against a background of higher prior exposure. That is a very different statement from ‘no evidence’, and it is why the conversation with a clinician is worth having rather than skipping.

What HPV does in the body, and which cancers are linked

HPV is an unusually quiet virus. It infects the thin layer of cells lining the skin and mucous membranes, and in most people it causes no symptoms at all before the immune system clears it. Around nine in ten infections resolve within two years. The problem is the tenth. When a high-risk type such as HPV 16 or 18 persists for years, it can disrupt the genes that control cell division, and over a decade or more the affected cells can progress through precancerous changes toward invasive cancer. This slow arc is precisely what makes screening so effective and what makes vaccination such a good long-term investment.

The list of cancers is longer than most people realise. Nearly all cervical cancers are caused by HPV. The virus also causes a large majority of anal cancers, a substantial share of vaginal, vulvar and penile cancers, and a rising proportion of cancers at the back of the throat, known as oropharyngeal cancers, which include the base of the tongue and tonsils. In the United States, the CDC estimates that HPV causes roughly 37,000 cancers a year, and oropharyngeal cancer has overtaken cervical cancer as the most common HPV-related cancer, with men affected several times more often than women.

Globally the picture is dominated by cervical cancer. The WHO reports about 660,000 new cases and 350,000 deaths in 2022, the vast majority in countries without organised screening or vaccination programs. That gap is why the WHO has set an elimination target and why its guidance leans so heavily on vaccinating girls before exposure.

Low-risk types matter too. HPV 6 and 11 cause about 90 percent of genital warts, which are not cancerous but are common, distressing and included in the 9-valent vaccine’s coverage. For adults weighing vaccination, it helps to remember that the vaccine targets a defined set of types, and protection against any one of them is only relevant if you have not already met it. Understanding this is the difference between a hopeful guess and an informed choice.

Which HPV vaccine adults receive and what it covers

Only one HPV vaccine is currently distributed in the United States: the 9-valent vaccine, so called because it targets nine HPV types. Seven of those are high-risk types responsible for the great majority of HPV-related cancers, including types 16 and 18, which together account for about 70 percent of cervical cancers, plus five further types that push coverage toward 90 percent. The remaining two are the low-risk types behind most genital warts. Earlier vaccines covering two or four types are no longer used in the US, though anyone who completed a series with them is considered protected against the types those vaccines covered and is not routinely re-vaccinated.

The vaccine contains no live virus. It is made from virus-like particles, hollow protein shells that mimic the outside of HPV closely enough to trigger antibodies but contain no viral DNA, so they cannot cause infection or cancer. This is why the vaccine is safe for people with weakened immunity and why it cannot ‘give you HPV’, a fear that still circulates online.

The number of doses in a series depends on age at the first dose and on immune status, and it is set by the prescribing clinician according to CDC schedules; this article deliberately does not list dose counts or intervals, because the right schedule is an individual medical decision. What is worth knowing is that the series does not need to be restarted if it is interrupted, and that adults who received some doses years ago and are unsure how many can discuss completing rather than repeating the series.

Adults sometimes ask whether a newer or ‘stronger’ product is on the horizon. Research into next-generation vaccines and therapeutic vaccines, which aim to treat existing infections rather than prevent new ones, is ongoing, but no therapeutic HPV vaccine is approved anywhere. Anything marketed as such today is investigational or unproven and not for self-use. The licensed preventive vaccine remains the only evidence-based option.

Does the HPV vaccine help if you already have HPV or had an abnormal screen?

This is the question adults most often whisper rather than ask, and it deserves a straight answer. The vaccine does not treat an existing HPV infection, does not clear abnormal cells, and does not lower the risk that a current persistent infection progresses. Trials that included women already infected with a vaccine type at enrolment showed no effect on that infection. Guidance is unambiguous: vaccination is prevention, not therapy.

That does not make vaccination pointless after a diagnosis. An abnormal cervical screen or a positive HPV test tells you that at least one type is present, not which types, and certainly not that you carry all nine covered by the vaccine. Someone infected with HPV 16 remains susceptible to HPV 18, 31, 33 and the rest. The CDC notes that people with a history of abnormal screening results, genital warts or a positive HPV test can still be vaccinated, and that testing for HPV before vaccination is not recommended because it does not usefully guide the decision.

A more specific claim has circulated: that vaccinating people who have just had treatment for cervical precancer reduces the chance of the abnormality returning. Several observational studies and pooled analyses have reported lower recurrence in vaccinated women, and the pattern is biologically plausible if treatment removes the infected cells and the vaccine then blocks reinfection. The evidence, however, is observational and inconsistent across studies, and randomized trials are still underway. Current CDC guidance does not include a recommendation to vaccinate specifically for this purpose. Anyone in this situation should ask the clinician managing their care what the latest evidence shows and follow that advice, rather than treating the idea as settled.

Two practical points close this out. First, being vaccinated after an abnormal result does not change your screening interval; you still return for follow-up exactly as advised. Second, a past infection is not a mark against you. HPV is the most common sexually transmitted infection in the world, and nearly every sexually active adult meets it. The vaccine conversation should feel like planning, not judgment.

HPV vaccine side effects in adults and the safety record

More than 135 million doses of HPV vaccine had been distributed in the United States by the early 2020s, and the safety monitoring systems that track vaccines nationally have found no serious safety signal in nearly two decades of use. That is a substantial body of real-world data, and it is consistent with what the original trials showed.

The common effects are the ones you would expect from any injection into the upper arm. Soreness, redness or swelling at the site is reported by most recipients and settles within a day or two. Some people notice a mild headache, tiredness, muscle aches, or a low-grade fever. Nausea has been reported. Fainting shortly after vaccination has been documented, mainly in adolescents, which is why clinics routinely ask people to sit for about fifteen minutes afterward; adults are less prone to it but the precaution applies to everyone.

Serious allergic reactions can occur with any vaccine and are very rare, on the order of a few cases per million doses. Anyone with a severe allergy to yeast or to any vaccine component should tell their clinician beforehand, because the 9-valent vaccine is produced using yeast. The vaccine is not recommended during pregnancy, not because harm has been shown, but because pregnant people were excluded from trials; anyone who discovers they are pregnant midway through a series simply pauses and resumes afterward, and pregnancy testing before vaccination is not required.

Two fears merit direct rebuttal because they are widespread. Claims that the vaccine causes infertility or premature ovarian failure have been examined in large studies, including a US analysis of nearly 200,000 young women, and no association has been found. Claims linking the vaccine to chronic fatigue, autoimmune conditions or postural tachycardia syndrome have likewise been investigated in national registry studies in Denmark, Sweden and elsewhere without evidence of a causal link. Adults in their thirties and forties have shown side-effect profiles similar to younger recipients in the available trials. The safety picture is one of the more reassuring in modern vaccinology, and it is a legitimate part of any shared decision.

HPV self test kits and screening: why vaccination never replaces a cervical screen

The arrival of the hpv self test is the other half of this year’s story, and it is worth separating cleanly from vaccination. A self-test, more precisely called self-collection, means a person uses a small swab to collect a sample from the vagina, which a laboratory then tests for high-risk HPV types. It does not look at cells under a microscope the way a traditional Pap test does; it detects the virus. In 2024 US regulators approved self-collection in health-care settings such as clinics and pharmacies, and in May 2025 an at-home kit was approved for use with a prescription and clinician follow-up.

Why does this matter for a vaccine article? Because the two tools do different jobs and neither substitutes for the other. The vaccine blocks future infection with nine types. Screening finds persistent infection or cell changes from any high-risk type, including types not covered by the vaccine and infections acquired before vaccination. Even the most thoroughly vaccinated adolescent will grow into an adult who needs screening. An adult vaccinated at 38 needs screening more than ever, because the vaccine can do nothing about exposures from the previous two decades.

Screening ages, not symptoms, are the right frame here. US guidelines generally begin cervical screening at age 21 and continue to 65, with HPV testing either alone or combined with a Pap test becoming an option from the late twenties or thirty depending on the guideline followed. The NHS invites people with a cervix from age 25 to 64. A clinician will advise which test and interval apply to you.

Self-collection has been studied extensively, and large trials have shown that it detects high-risk HPV about as accurately as clinician-collected samples. Its real promise is reaching the roughly one in four eligible US women who are overdue for screening, often because a speculum exam feels intrusive or is hard to fit around work and caregiving. A positive self-test result is not a diagnosis; it leads to follow-up testing that a clinician arranges. Think of the vaccine and the swab as a lock and a smoke detector. You want both, and neither one makes the other unnecessary.

Common myths about the HPV vaccine for adults

The viral claims driving this topic fall into a few repeating patterns. Each deserves a plain correction.

‘If you are over 26 it is too late.’ The US license runs to 45, the CDC explicitly supports a shared decision for 27 to 45, and a randomized trial in women aged 24 to 45 demonstrated protection against covered types in those not already infected. Benefit is smaller on average than in teenagers, but ‘smaller’ is not ‘zero’.

‘The vaccine works just as well at 40 as at 12.’ Also untrue. The vaccine’s power comes from arriving before exposure. Population studies show the reduction in cervical cancer is far larger when vaccination precedes sexual activity. Adults can benefit, but anyone selling the vaccine as equally effective at any age is overstating the evidence.

‘You can get tested to see whether you need it.’ No test in routine use tells you which of the nine vaccine types you have and have not met. Antibody tests are unreliable for past infection, and cervical HPV tests report only high-risk positivity. Guidance recommends against testing to decide eligibility.

‘If you already have HPV, the vaccine will clear it.’ It will not. The vaccine prevents new infections and has no effect on existing ones or on abnormal cells. Anyone with a diagnosis follows their clinician’s follow-up plan regardless of vaccination.

‘Vaccinated adults can skip screening.’ The vaccine covers nine types; screening detects persistent infection from all high-risk types, including those acquired before vaccination. Screening continues to 65 in the US and 64 in England for everyone with a cervix.

‘An at-home HPV self test replaces the vaccine.’ Different tool, different job. Self-collection finds infections already present; it prevents nothing.

‘The vaccine causes infertility or chronic illness.’ Large registry studies across several countries have found no such link, and the vaccine contains no viral DNA capable of causing infection.

Every one of these myths contains a grain that makes it plausible, which is why they spread. The full picture is more useful, and it fits in a single conversation with a clinician.

When to see a doctor about HPV vaccination or HPV-related concerns

Vaccination decisions for adults are meant to happen in a clinic, not a comment thread, so the first reason to see a clinician is simply to have the shared decision-making conversation the CDC describes. Bring your vaccination history if you have it, an honest account of your relationship circumstances, and any medical conditions or treatments that affect your immune system. Expect a matter-of-fact discussion, not a lecture. The clinician makes the prescribing decision and sets the schedule.

Book an appointment sooner rather than later if you are 26 or younger and unvaccinated, because that is the group with the strongest evidence of benefit and a clear catch-up recommendation. Adults with a new diagnosis of HIV, an organ transplant, or a course of immune-suppressing treatment should also raise HPV vaccination and screening with their care team, since persistent HPV infection is more common when immunity is weakened.

Some situations call for prompt medical attention regardless of vaccination status. These are red flags, not a self-diagnosis checklist, and they warrant a clinical assessment rather than an internet search:

• Bleeding between periods, after sex, or after menopause
• Persistent unusual vaginal discharge, pelvic pain or pain during intercourse
• Rectal bleeding, a persistent anal lump or change in bowel habit
• A sore throat, hoarseness or difficulty swallowing lasting more than three weeks, or a painless lump in the neck
• New genital or anal growths, or a change in an existing one
• A positive HPV self-collection result, which always requires clinician follow-up

After a vaccine dose, seek urgent care for signs of a severe allergic reaction: difficulty breathing, swelling of the face or throat, a fast heartbeat, or widespread hives, especially within minutes to an hour of the injection. A very sore arm, tiredness or mild fever for a day or two does not need medical review unless it worsens or persists.

Finally, if you are overdue for cervical screening, that is itself a reason to see a clinician, and it does not require any symptoms. Screening is the intervention with the strongest evidence for adults over 45, and it is the one most often postponed.

Frequently asked questions

Should adults get vaccinated for HPV?

Adults through age 26 who were not fully vaccinated should catch up, according to CDC guidance. For ages 27 to 45 the CDC recommends a shared decision with a clinician, because most people that age have already met some HPV types and average benefit is smaller. Adults with likely new partners or weakened immunity may still gain protection. The decision rests with the prescribing clinician.

When is it too late to get vaccinated for HPV?

There is no fixed age at which the vaccine stops working; what declines is how much unexposed future remains for it to protect. The US license ends at 45 because trials have not studied older adults. Benefit is highest before sexual activity begins and drops steadily afterward, but a 30- or 40-year-old with limited past exposure and likely new exposure can still benefit.

Can you get the HPV vaccine over 45?

Not under the current US license, and the CDC does not recommend it above 45. No efficacy or safety trial has enrolled people older than that, so there is no direct evidence either way. Prescribing beyond the licensed age would be off-label and is not encouraged here. For adults over 45, cervical screening to age 65 is the evidence-based way to address HPV-related risk.

Is it worth getting the HPV vaccine at 40?

It depends on your circumstances, which is exactly why the CDC uses shared clinical decision-making for this age. Someone newly dating after a long relationship, or someone with an immune-suppressing condition, may gain real protection against types they have not yet met. Someone in a long monogamous relationship expecting no new partners gains little. A clinician can weigh these factors with you.

Does the HPV vaccine work if you already have HPV?

It does not treat or clear an existing infection or abnormal cells. Trials found no effect on HPV types a person already carried at enrolment. It can still protect against the other covered types you have not encountered, so a past positive result does not rule vaccination out. Testing for HPV before vaccination is not recommended because it cannot show which of the nine types you have met.

Do men need the HPV vaccine as adults?

The same CDC age guidance applies to men: catch-up through 26 and shared decision-making from 27 to 45. HPV causes anal, penile and throat cancers as well as genital warts, and throat cancer is now the most common HPV-related cancer in the US, mainly in men. The NHS offers vaccination up to 45 to men who have sex with men because their anal cancer risk is higher.

What is an HPV self test and does it replace the vaccine?

An HPV self test, or self-collection, is a swab you take yourself from the vagina that a laboratory tests for high-risk HPV types. US regulators approved it in clinics in 2024 and as an at-home kit in May 2025. It detects infections already present and requires clinician follow-up if positive. It does not prevent infection, so it complements the vaccine rather than replacing it.

What are the HPV vaccine side effects in adults?

Most adults notice a sore, red or swollen arm for a day or two. Some have a mild headache, tiredness, muscle aches, nausea or low-grade fever. Fainting shortly after injection is documented, mainly in teenagers, so clinics ask everyone to sit briefly afterward. Serious allergic reactions are very rare. Large national studies have found no link to infertility, autoimmune disease or chronic fatigue.

Can you get the HPV vaccine while pregnant or trying to conceive?

The vaccine is not recommended during pregnancy, not because harm has been shown but because pregnant people were excluded from trials. If pregnancy is discovered partway through a series, the remaining doses are simply postponed until afterward. Pregnancy testing before vaccination is not required. People who are breastfeeding can be vaccinated. Discuss timing with your clinician if you are planning a pregnancy.

Do vaccinated adults still need cervical screening?

Yes, without exception. The vaccine covers nine HPV types, while screening detects persistent infection or cell changes from any high-risk type, including infections acquired before vaccination. US guidelines generally screen from 21 to 65 and the NHS from 25 to 64. An adult vaccinated in their thirties or forties has two decades of prior exposure that only screening can address.

References

• CDC – HPV Vaccination
• NHS – HPV vaccine
• WHO – Human papillomavirus and cancer fact sheet
• MedlinePlus – HPV

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.